Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 3
2017 2
2020 2
2021 8
2022 4
2023 3
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, McEvoy C, DeJesus E, Hassman M, Little SJ, Pahud BA, Durbin A, Pickrell P, Daar ES, Bush L, Solis J, Carr QO, Oyedele T, Buchbinder S, Cowden J, Vargas SL, Guerreros Benavides A, Call R, Keefer MC, Kirkpatrick BD, Pullman J, Tong T, Brewinski Isaacs M, Benkeser D, Janes HE, Nason MC, Green JA, Kelly EJ, Maaske J, Mueller N, Shoemaker K, Takas T, Marshall RP, Pangalos MN, Villafana T, Gonzalez-Lopez A; AstraZeneca AZD1222 Clinical Study Group. Falsey AR, et al. N Engl J Med. 2021 Dec 16;385(25):2348-2360. doi: 10.1056/NEJMoa2105290. Epub 2021 Sep 29. N Engl J Med. 2021. PMID: 34587382 Free PMC article. Clinical Trial.
Risk of COVID-19 after natural infection or vaccination.
Rick AM, Laurens MB, Huang Y, Yu C, Martin TCS, Rodriguez CA, Rostad CA, Maboa RM, Baden LR, El Sahly HM, Grinsztejn B, Gray GE, Gay CL, Gilbert PB, Janes HE, Kublin JG, Huang Y, Leav B, Hirsch I, Struyf F, Dunkle LM, Neuzil KM, Corey L, Goepfert PA, Walsh SR, Follmann D, Kotloff KL; NIAID-funded COVID-19 Prevention Network (CoVPN). Rick AM, et al. EBioMedicine. 2023 Oct;96:104799. doi: 10.1016/j.ebiom.2023.104799. Epub 2023 Sep 20. EBioMedicine. 2023. PMID: 37738833 Free PMC article. Clinical Trial.
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.
Theodore DA, Branche AR, Zhang L, Graciaa DS, Choudhary M, Hatlen TJ, Osman R, Babu TM, Robinson ST, Gilbert PB, Follmann D, Janes H, Kublin JG, Baden LR, Goepfert P, Gray GE, Grinsztejn B, Kotloff KL, Gay CL, Leav B, Miller J, Hirsch I, Sadoff J, Dunkle LM, Neuzil KM, Corey L, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y; COVID-19 Prevention Network (CoVPN). Theodore DA, et al. JAMA Netw Open. 2023 Jul 3;6(7):e2323349. doi: 10.1001/jamanetworkopen.2023.23349. JAMA Netw Open. 2023. PMID: 37440227 Free PMC article.
Risk Factors for Ebola Virus Persistence in Semen of Survivors in Liberia.
Dyal J, Kofman A, Kollie JZ, Fankhauser J, Orone R, Soka MJ, Glaybo U, Kiawu A, Freeman E, Giah G, Tony HD, Faikai M, Jawara M, Kamara K, Kamara S, Flowers B, Kromah ML, Desamu-Thorpe R, Graziano J, Brown S, Morales-Betoulle ME, Cannon DL, Su K, Linderman SL, Plucinski M, Rogier E, Bradbury RS, Secor WE, Bowden KE, Phillips C, Carrington MN, Park YH, Martin MP, Aguinaga MDP, Mushi R, Haberling DL, Ervin ED, Klena JD, Massaquoi M, Nyenswah T, Nichol ST, Chiriboga DE, Williams DE, Hinrichs SH, Ahmed R, Vonhm BT, Rollin PE, Purpura LJ, Choi MJ. Dyal J, et al. Among authors: purpura lj. Clin Infect Dis. 2023 Feb 8;76(3):e849-e856. doi: 10.1093/cid/ciac424. Clin Infect Dis. 2023. PMID: 35639875 Free PMC article.
SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease.
Wang P, Liu L, Nair MS, Yin MT, Luo Y, Wang Q, Yuan T, Mori K, Solis AG, Yamashita M, Garg A, Purpura LJ, Laracy JC, Yu J, Joshua-Tor L, Sodroski J, Huang Y, Ho DD. Wang P, et al. Among authors: purpura lj. Emerg Microbes Infect. 2020 Dec;9(1):2091-2093. doi: 10.1080/22221751.2020.1823890. Emerg Microbes Infect. 2020. PMID: 32930052 Free PMC article.
What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak.
Mehta M, Purpura LJ, McConville TH, Neidell MJ, Anderson MR, Bernstein EJ, Dietz DE, Laracy J, Gunaratne SH, Miller EH, Cheng J, Zucker J, Shah SS, Chaudhuri S, Gordillo CA, Patel SR, Guo TW, Karaaslan LE, Reshef R, Miko BA, Bathon JM, Pereira MR, Uhlemann AC, Yin MT, Sobieszczyk ME. Mehta M, et al. Among authors: purpura lj. PLoS One. 2021 Apr 8;16(4):e0249349. doi: 10.1371/journal.pone.0249349. eCollection 2021. PLoS One. 2021. PMID: 33831046 Free PMC article. Clinical Trial.
Development and performance of a point-of-care rapid antigen test for detection of SARS-COV-2 variants.
Liu L, Meyers K, Purpura LJ, Nguyen N, Mohri H, Chang JY, Annavajhala MK, Lopez L 3rd, Lee SW, Shah J, Lane B, Cantos A, Tukuru SA, Guo Y, Ford K, Chiu YT, Sheng Z, Choesang T, Castor D, Wang M, Pili C, Van Hoy MN, Wallach A, Horton J, Chen Z, Rosenthal S, McLaren S, Jiang B, Wang F, Lu HH, Uhlemann AC, Ho DD, Yin MT. Liu L, et al. Among authors: purpura lj. J Clin Virol Plus. 2022 Aug;2(3):100080. doi: 10.1016/j.jcvp.2022.100080. Epub 2022 May 4. J Clin Virol Plus. 2022. PMID: 35528048 Free PMC article.
20 results